HTHT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HTHT is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who wants to act now. The business outlook is constructive and analysts remain bullish, but the current technical setup is weak, there is no strong proprietary buy signal today, and the stock is trading below key resistance with short-term downside bias. If you need to buy immediately, I would not call this a good entry right now; I would wait for a clearer technical reversal or a stronger pullback-confirmation setup.
Current price is 45.42 in pre-market, down 0.40%, with S&P 500 pre-market also weak at -1.04%. The trend is bearish in the near term: MACD histogram is -0.476 and still expanding negatively, which signals downside momentum. RSI_6 at 24.737 suggests the stock is oversold, but not yet showing a clean reversal signal. Moving averages are converging, which can precede a trend change, but price remains below the pivot at 48.336 and below R1 at 50.829. Immediate support is near S1 45.843 and S2 44.304, so the stock is sitting near support rather than breaking higher. The pattern-based forecast also leans negative for the near term, with a 70% chance of -1.16% next day, -2.16% next week, and -1.14% next month.
["Analysts remain positive across Citi, Benchmark, Macquarie, and UBS, with Buy/Outperform ratings and price targets around $59-$62.40.", "Citi added an upside 30-day catalyst watch, expecting decent RevPAR trends into the Labor Day holiday period.", "The upcoming Q1 earnings release is expected to show strong growth, with estimated EPS of $0.57 and revenue of $869.71 million.", "Management guidance and analyst commentary point to continued hotel openings, margin expansion, and an asset-light strategy."]
["Short-term price action is weak, with MACD negative and expanding lower.", "The stock is below the pivot level and near support, which means it has not confirmed a rebound yet.", "The pattern-based trend estimate is bearish over the next day, week, and month.", "No recent congress trading data is available.", "Hedge funds and insiders are neutral, with no meaningful accumulation signal.", "There is no AI Stock Picker or SwingMax buy signal today."]
Latest quarter financials are not directly provided in the financial snapshot, but analyst commentary on the recent Q4 report was strong: Macquarie said Q4 revenue rose 8.3% year over year and adjusted EBITDA rose 83% year over year, both beating consensus. Revenue per available room recovery remains on track, and overseas RevPAR rose 7.4% year over year. Analysts also highlighted margin expansion from the asset-light strategy and management's plan for about 1,600 new hotel openings in 2026, with revenue expected to grow 2%-6% year over year. The next reported season is Q1 2026, with earnings scheduled pre-market on 2026-05-15.
Analyst sentiment is clearly positive and has improved recently. Citi maintained Buy with a $59 target and added a 30-day catalyst watch. Benchmark raised its target to $60 from $52 and kept Buy. Macquarie raised its target to $62 from $59 and kept Outperform. UBS upgraded the stock to Buy from Neutral with a $62.40 target. Wall Street pros are constructive on RevPAR recovery, margin expansion, and valuation versus peers, while the main con is that the stock's current technical momentum is weak and the near-term setup has not yet confirmed upside.
